ELV Q3 deep dive: Carelon expansion and Medicaid margin actions underpin raised outlook

Health insurance provider Elevance Health (NYSE:ELV) reported Q3 2026 results beating Wall Street’s revenue expectations, but sales were flat year on year at $50.44 billion. Its non-GAAP profit of $6.99 per share was 48.9% above analysts’ consensus estimates.